Back to Search Start Over

Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients

Authors :
Mehdi Yaseri
Hosein Ameri
Mohammad Arab
Mahmood Yousefi
Azin Nahvijou
Ali Akbari Sari
Source :
Expert Review of Pharmacoeconomics & Outcomes Research. 19:89-96
Publication Year :
2018
Publisher :
Informa UK Limited, 2018.

Abstract

Introduction: Economic evaluation of healthcare interventions usually needs accurate data on utility and health-related quality-of-life scores. The aim of this study is to map QLQ-C30 scale score onto EQ-5D-5L and SF-6D utility values in colorectal cancer (CRC) patients. Methods: EQ-5D-5L, SF-6D, and QLQ-C30 were completed by 252 patients with CRC who were referred to three cancer centers in Tehran between May and September 2017. Moreover, OLS, Tobit, and CLAD models were used to predict EQ-5D-5L and SF-6D values. The goodness of fit of models was evaluated using Pred R2 and Adj R2. In addition, their predictive performance was assessed by MAE, RMSE, ICC, MID, and Spearman’s correlation coefficients between observed and predicted EQ-5D-5L and SF-6D values. Models were validated using a 10-fold cross-validation method. Results: Considering the goodness of fit and predictive ability of models, the OLS Model 2 performed best for EQ-5D-5L (Adj R2 = 58.09%, Pred R2 = 58.93%, MAE = 0.0932, RMSE = 0.129) and the OLS Model 3 performed best for SF-6D (Adj R2 = 54.90%, Pred R2 = 55.62%, MAE = 0.0485, RMSE = 0.0634). Conclusion: Our results demonstrated that algorithms developed based on OLS Models 1 and 2 are the best for predicted EQ-5D-5L and SF-6D values, respectively.

Details

ISSN :
17448379 and 14737167
Volume :
19
Database :
OpenAIRE
Journal :
Expert Review of Pharmacoeconomics & Outcomes Research
Accession number :
edsair.doi.dedup.....d8cbb5754940c1861f9c4a0dff54fb6a
Full Text :
https://doi.org/10.1080/14737167.2018.1517046